Evaluation of efficacy and safety of sequential antibody drug conjugates (ADCs) in human epidermal growth factor 2 (HER2)-negative metastatic breast cancer
Sara Nezirevic(Vanderbilt University Medical Center), Heather M. Moore(Biomarker Technologies (China)), Alaattin Erkanli(Duke University), Carey K. Anders(Duke University), Zidanyue Yang(Duke University), Susan Dent(Washington Hospital), Rani Bansal(Duke Medical Center)
Cited by 3
Related Papers
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
|New England Journal of Medicine|2019|1.3k
Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2017|1.3k
Brain metastases
|Nature Reviews Disease Primers|2019|1.1k
Young Age at Diagnosis Correlates With Worse Prognosis and Defines a Subset of Breast Cancers With Shared Patterns of Gene Expression
|Journal of Clinical Oncology|2008|917
Breast Cancer Before Age 40 Years
|Seminars in Oncology|2009|795